, Jacinta L Johnson 4, 5 C odeine is globally the most frequently used opiate, 1 and its consumption is increasing. In Australia, 27 780 234 packs of codeine-containing analgesics were supplied by community pharmacies during 2013, a rate of 1.24 packs per person. 2 In New Zealand, most of Canada, South Africa, Ireland, and the United Kingdom, codeine is available over the counter, usually combined with simple analgesics such as paracetamol or ibuprofen; 3 until recently, it was also available without prescription in Australia and France. Products containing greater amounts of codeine are generally only available on prescription. 3 Codeine has low affinity for and intrinsic activity at m-opioid receptors, and is considered a prodrug; its analgesic effects depend largely on its being converted to morphine by the polymorphic cytochrome P450 isoenzyme (CYP) 2D6. 4, 5 Genetic variability in the activity of CYP2D6 underlie interperson differences in the analgesia achieved and the risk of opioid toxicity. 6 Tolerance can develop after a relatively short period of regular use. [7] [8] [9] In view of the limited evidence that adding low dose codeine (< 30 mg) to simple analgesics increases pain relief, [10] [11] [12] [13] [14] [15] the variability in its metabolism, and the availability of opioids with more predictable effects, the role of codeine in pain management is contentious. 16, 17 The liability of codeine to be misused has been shown in a randomised, double blind, placebo-controlled drug administration study, 18 and has been documented in several case series. 19, 20 Although the prevalence of codeine dependence is unknown, the harms associated with overuse are well established, including serious morbidity causing great cost to the health care system. 21 Some harms associated with codeine overuse are directly related to prolonged intake, but many serious consequences stem from concomitant overconsumption of ibuprofen or paracetamol in combination products. 19 Sequelae of supratherapeutic ibuprofen ingestion secondary to codeine dependence that require intensive care have been described, including several codeine-related deaths. 22 As a result, access to over-the-counter codeine has been restricted or removed in Manitoba (February 2016), France (July 2017), and Australia (February 2018). [23] [24] [25] In order to respond appropriately, we need to identify people who are codeine-dependent. There has been greater awareness of dependence with the imminent rescheduling of codeine in Australia. Both in Australia and internationally, presentations to addiction treatment services have increased, [26] [27] [28] but treatment approaches for codeine dependence are poorly defined. The purpose of our systematic review was to identify the characteristics of people who are codeinedependent, and to define approaches for identifying codeine dependence.
Methods

Search strategy
We searched MEDLINE and EMBASE on 22 November 2016 for the following terms: "codeine", "dependence", "substance-related disorders", "opioid-related disorders", "behaviour, addictive", and "substance withdrawal syndrome" (online Appendix, table 1). We restricted our search to human studies published in English;
Abstract
Objectives: Codeine dependence is a significant public health problem, motivating the recent rescheduling of codeine in Australia (1 February 2018) . To provide information for informing clinical responses, we undertook a systematic review of what is known about identifying and treating codeine dependence.
Study design: Articles published in English that described people who were codeine-dependent or a clinical approach to treating people who were codeine-dependent, without restriction on year of publication, were reviewed. Articles not including empirical data were excluded. One researcher screened each abstract; two researchers independently reviewed full text articles. Study quality was assessed, and data were extracted with standardised tools.
Data sources: MEDLINE and EMBASE were searched for relevant publications on 22 November 2016. The reference lists of eligible studies were searched to identify further relevant publications. 2150 articles were initially identified, of which 41 were eligible for inclusion in our analysis.
Data synthesis: Studies consistently reported specific characteristics associated with codeine dependence, including mental health comorbidity and escalation of codeine use attributed to psychiatric problems. Case reports and series described codeine dependence masked by complications associated with overusing simple analgesics and delayed detection. Ten studies described the treatment of codeine dependence. Three reports identified a role for behavioural therapy; the efficacy of CYP inhibitors in a small open label trial was not confirmed in a randomised controlled trial; four case series/chart reviews described opioid agonist therapy and medicated inpatient withdrawal; two qualitative studies identified barriers related to perceptions of codeine-dependent people and treatment providers, and confirmed positive perceptions and treatment outcomes achieved with opioid agonist treatments.
Conclusion:
Strategies for identifying problematic codeine use are needed. Identifying codeine dependence in clinical settings is often delayed, contributing to serious morbidity. Commonly described approaches for managing codeine dependence include opioid taper, opioid agonist treatment, and psychological therapies. These approaches are consistent with published evidence for pharmaceutical opioid dependence treatment and with broader frameworks for treating opioid dependence.
there was no restriction on year of publication. The reference lists of eligible studies were searched to identify further relevant publications.
One reviewer (SN, JJ or TM) independently examined the titles and abstracts of identified articles. The full text of relevant articles was independently assessed for inclusion by two authors, and reasons for exclusion documented as appropriate. Inter-reviewer disagreement about inclusion was resolved by consensus among all three authors.
Study inclusion criteria
We included studies that described people who were codeinedependent (identification studies) or any clinical approach for treating people who were codeine-dependent (treatment studies).
Data extracted from identification studies included study characteristics (author, location, design, quality rating) and population characteristics (participant age, sex, employment, mental health, pain and substance use history, adverse effects related to codeine use, and management of adverse effects).
Treatment studies included randomised and non-randomised controlled trials, quasi-experimental, before-and-after studies, prospective and retrospective cohort studies, caseecontrol studies, analytic cross-sectional studies, qualitative studies, and case reports and series. Treatment outcome measures included change in codeine use (days of use or amount used), retention in treatment, adverse events and other outcomes related to codeine use, opioid dependence, and pain.
Exclusion criteria
Reports limited to describing the clinical applications or pharmacology of codeine or other opioids, reports that did not separately report codeine-related data, and articles without empirical data (eg, letters, commentaries, reviews) were excluded (online Appendix, table 2).
Assessment of methodological quality (identification studies)
The quality of descriptive studies was assessed with a modified version of the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Analytical Cross Sectional Studies. 29 To enable application of a single tool to all study methodologies, the JBI tool was reduced from eight to five items, and an item from the Evidence-Based Librarianship (EBL) Critical Appraisal Tool for assessing sample bias was added 30 (online Appendix, table 3). The range for total scores was 0e6, higher scores reflecting higher quality.
Grading of evidence (treatment studies)
Studies examining treatment approaches were scored for quality according to GRADE criteria. 31 
Data collection
Data were extracted with a standardised data extraction tool into an Excel (Microsoft) spreadsheet. The tool was piloted and reviewed before being finalised.
Data synthesis
Findings were qualitatively and quantitatively synthesised when population characteristics were reported in a manner that enabled this approach. Meta-analysis of treatment studies was not possible because of the heterogeneity of study designs. When individual patient data were reported, details were extracted at the patient level to enable synthesis of patient characteristics.
Results
Of the 2150 articles initially identified, 41 were eligible for inclusion in our analysis (Box 1). The mean study quality score of the included articles was 3.0 (standard deviation [SD], 1.1).
Identifying codeine dependence Fourteen reports described samples of patients who were codeine-dependent (Box 2; online Appendix, table 4A); 22 described presentations by individual patients (Box 3, Box 4; online Appendix, tables 4B and C). No studies reported developing an approach for identifying people with codeine dependence as an aim, but two reported applying the Severity of Dependence Scale (SDS) 32 for defining codeine dependence (cut-off score, 5).
33,34
Analyses of administrative data Three studies examined data from administrative sources on the treatment of people for opioid dependence. 28, 35, 36 An Australian study compared codeine-related treatment episodes with those for patients for whom another prescribed opioid or heroin was the chief drug of concern. The proportion of women among those treated for codeine dependence declined from 70% in 2002 to 47% in 2011; people for whom codeine was the drug of concern were on average older and less likely to have a history of intravenous and illicit substance use than those treated for misuse of stronger prescription opioids or heroin. 28 A study of codeine prescriptions in Norway found that 0.5% of all codeine recipients in 2005 were likely to be using codeine problematically (annual prescription level exceeding twice the maximum daily dose for 12 months); further, high dose prescribing of benzodiazepines was more prevalent in this group. 35 A South African study of national data on treatment for substance misuse (alcohol, pharmaceutical and illicit drugs) found that 2.5% of admissions involved codeine, and that codeine was recorded as the primary substance of concern for 0.8% of patients. 36 Quantitative convenience samples Two studies included convenience samples of people who reported using codeine. In an Australian web-based survey, 137 codeine-dependent participants were compared with 633 nondependent participants; characteristics associated with dependence (assessed with the SDS) included taking higher than recommended doses, experiencing psychological distress, previous drug treatment, and chronic pain. 33 A 1999 Canadian postal survey on prescribed and over-the-counter codeine (participants recruited via newspaper advertisements) found that 37% of respondents met DSM-IV criteria for codeine dependence, most of whom reported chronic pain and family histories of substance use problems. 20 Caseecontrol study A prospective caseecontrol study described patients attending an addiction medicine clinic in China who were dependent on a codeine-containing cough syrup. 37 This imaging study found that the patients, who exhibited increased impulsivity, had cortical white matter microstructural abnormalities. 37 Qualitative studies Three qualitative studies have examined the perceptions of pharmacists and codeine-dependent people. 34, 38, 39 A British author 38 described the perception that dependence is not identified early, the challenges posed by the stigma attached to dependence, the fact that codeine-dependent people saw themselves as different to users of illicit opioids, and medical reasons for initiating codeine use. 38 A recent Irish study similarly described social stigma as a treatment barrier, and reported emotional distress as a driver for codeine use. 34 Two typologies of codeine dependence have been proposed:
38,39 users who do not exceed therapeutic doses, and codeine-dependent people who consume high doses of the drug. The second group is characterised by severe dependence and harms. Additional typologies include recreational users 39 and people who slightly exceed recommended doses. 38 Retrospective chart reviews and case series Five case series or retrospective chart reviews 19, [40] [41] [42] [43] identified common features of people with codeine dependence, including higher proportions of women than among those treated for misuse of other opioids, histories of problematic alcohol use, mental health comorbidity, and serious side effects resulting from using combination medicines containing codeine, including one death. 41 Prior heroin dependence was rare.
Reports on individual patients Twenty-two reports described 49 individuals who were codeinedependent (Box 3, Box 4; online Appendix, tables 4B and 4C). Twenty-three were women (mean age, 42 years [SD, 9 years]). Of the 15 people for whom data on employment status were reported, nine were employed. Acute harms and information on treatment approaches were described. Inherent to cases of acute harm were complications attributable to the co-medications paracetamol and ibuprofen, including distal renal tubular acidosis, hypokalaemia, gastritis and other enteropathies, medication overuse headache, hepatic necrosis, hypoalbuminaemia, microcytic anaemia, and weight loss. In a case series of 27 patients, 19 most had initiated codeine to treat pain but later escalated their intake for other reasons; this was also reported in many case reports.
Acute management of harms was characterised by inpatient hospital management of serious problems (often requiring intensive care) to restore electrolyte balance, 47, 58, 59 manage gastrointestinal symptoms 44, 53 (including bowel resection), 56 and to assess or treat hepatotoxicity. 50, 64 Opioid withdrawal was managed with symptomatic medications and buprenorphine; potential hepatotoxicity was managed with acetylcysteine. 64 Psychiatric comorbidity in people with codeine dependence was dominated by high prevalence conditions (depression and anxiety disorders). 20, 27, 44, 48, 53, 58, 60, 61 Some reports described prior or comorbid addictions (benzodiazepines, opioids, alcohol), 34, 35, 40, 42, 60 and mental health conditions. 20, [40] [41] [42] 60 Bipolar disorder, 27, 42 obsessiveecompulsive disorder, 62 relationship breakdown, 47 suicide behaviour, 51, 56 and bereavement or loss 47 were also described.
Individual patient reports described treatment approaches, including attempted self-management, 45 ,65 use of symptomatic medications, 60 prescribed codeine or dihydrocodeine 49, 52 or buprenorphine and naloxone, 52, 54, 65 and detoxification with methadone. 48 Management of mental health symptoms with antidepressants and behavioural therapies was described. 48, 54, 55, 65 One notable case combined methadone taper, cognitive behavioural therapy, and relaxation strategies, enabling codeine cessation and self-management of pain. 48 Resolution of presenting complaints (obsessiveecompulsive disorder, medication overuse headache) after codeine cessation was described. 62, 63 Treatment studies Ten studies described treatment approaches in detail (Box 5; online Appendix, table 4D). Common medication-based approaches included taper from codeine with symptomatic medications such as clonidine or benzodiazepines, 42 ,67 buprenorphine maintenance, 19 ,27 CYP inhibitors, 66, 68 and gradual self-managed taper. 38 Positive outcomes for opioid agonist treatment (methadone and buprenorphine with or without naloxone) were described. 19, 27, 34, 38, 40, 43, 69 The role of internet support groups 38 and psychosocial treatments, including cognitive behavioural therapy, were highlighted in some studies. 42, 67, 69 Two studies tested the hypothesis that preventing the O-demethylation of codeine to morphine with CYP inhibitors would reduce codeine use. 66, 68 Initial promising results from an open label pilot study of fluoxetine (14 subjects) 66 were not replicated in a small randomised controlled trial that compared the effectiveness of fluoxetine or quinidine (two potent CYP2D6 inhibitors) with placebo. 68 A retrospective review of inpatient admissions described taper with clonidine and benzodiazepines, combined with an intensive 4-week mental health treatment program. 42 Patients had a mean stay of 42 days (SD, 23 days), with withdrawal symptoms requiring treatment for a mean 16 days (SD, 10 days). Taper with buprenorphine was described by an Australian study which noted that codeine dependence was more likely to be treated with taper rather than maintenance. 27 Relapse after taper was not uncommon. 34, 42 A single arm study (11 patients) found that cognitive behavioural therapy could significantly reduce codeine use -six patients ceased using codeine altogether -and neuropsychological functioning was improved by codeine reduction or cessation without deterioration in pain or quality of life. 67 A mixed methods study also highlighted the role of psychological therapies. 69 Seven studies described treatment with opioid agonists, 19, 27, 34, 38, 40, 43, 69 four of which did not report outcomes. 19, 34, 40, 69 One small retrospective cohort study described high retention rates for patients treated with buprenorphine over 28 days (median daily dose, 12e16 mg); one patient described initial sedation that necessitated reducing the dose. 43 Two qualitative studies described positive experiences and outcomes for treatment with methadone and buprenorphine, despite patient concerns about the treatment experience and the clinic environment. 34, 38 According to GRADE criteria, the quality of evidence from treatment studies was very low to low; most studies were retrospective and descriptive, and all had small sample sizes.
Discussion
Our review of codeine-dependent people indicates that approximately equal proportions of men and women are involved; their mean age is greater than for patients treated for problematic use of other opioids, the prevalence of mental health comorbidity is high, identification of dependence is often delayed, and patients experience serious complications associated with excessive consumption of combination products that include codeine. Problematic codeine use was associated with mental health problems. The quality and methodology of the studies we assessed varied considerably, but their depictions of the features associated with codeine dependence were consistent, describing a clinically challenging area in which under-reporting is highly likely. The reports highlight the importance of asking about the use of nonprescribed analgesics in a range of health care situations, particularly when gastrointestinal complications are identified. The diversity of those affected and the high level of morbidity suggest that population level interventions are required for screening and prevention wherever codeine is available over the counter. Careful questioning about recent patterns of use, the reasons for taking codeine, and withdrawal symptoms upon cessation may help identify when a patient should be comprehensively assessed for an opioid use disorder. Treatment approaches include self-management with internet support, psychological treatments, symptomatic medications for opioid withdrawal, and opioid agonist treatments. In particular, buprenorphine treatment undertaken according to current guidelines was commonly described. Studies of opioid taper found that relapse was common (consistent with taper for opioid dependence in general). Taken together, the treatment studies and case reports provide evidence that opioid agonist treatments, combined with psychosocial adjuncts, may be suitable and acceptable to patients. The evidence, albeit low in quality, indicates that positive treatment outcomes could be achieved with these approaches.
In the absence of specific high quality evidence, judgements about approaches for treating people with codeine dependence must be based largely on studies of opioid dependence. The effectiveness of treatment with methadone and buprenorphine has been reported, and maintenance is more effective than withdrawal and detoxification for people who are dependent on pharmaceutical opioids 70 or opioids in general. 71 Research on selecting patients for treatment with opioid agonists is limited. According to the general principles of treatment, diagnosis of opioid dependence must first be confirmed. 72 A stepped care approach with less intensive treatment (eg, taper, counselling) for low severity dependence is recommended by national guidelines. 72 Patients who unsuccessfully attempt taper may be considered for maintenance opioid agonist treatment, which achieves better treatment outcomes than detoxification for pharmaceutical opioid dependence. 71 Because of wide variations in codeine metabolism, predicting opioid requirements with dose conversion tables is challenging; 43 for this reason their use is discouraged.
Psychological adjunct therapies can be beneficial, 73 but the role of psychosocial interventions as accompaniments to opioid agonist treatments requires further research. 74 The high prevalence of mental health comorbidities and the preference of patients for online support may indicate that online interventions for managing comorbidity may be useful. In general, the role of pharmacological treatments for depression or anxiety at the start of treatment is unclear. It is recommended that comorbidities are assessed after a period of abstinence because of the potential for diagnostic uncertainty caused by the acute effects of opioid toxicity and withdrawal. 75 The treatment setting is also important. People consuming larger amounts of opioids together with sedatives (eg, benzodiazepines) are a population at greater risk, and referral to a specialist may be required. 72 Characteristics that may indicate that patients are appropriate for managing in primary care include being employed, having social support, and not having another substance use disorder or a history of illicit drug use.
Medication overuse headache
Headache is a common reason for initiating codeine use by patients who develop dependence. 19, 61 Paradoxically, medication overuse headache -in this context, exacerbation of a pre-existing headache disorder by excessive intake of codeineis another potential complication of codeine dependence. 48, 55, 63 Data that might guide the management of codeine overuse headache specifically have not been published. Management of opioid-related medication overuse headache usually consists of patient education, opioid withdrawal, and the initiation of prophylactic agents, [76] [77] [78] often in an inpatient setting. 76 Medication overuse headache that results from overusing analgesics, compared with overuse of triptans, is associated with a greater withdrawal headache duration (about 10 days), 79 with meaningful improvement only after 12 weeks or more, 80 and high relapse rates (eg, 71% at 4 years 81 ).
Limitations of our analysis
Comparing codeine dependence in different groups of patients was made difficult by changing usage patterns over time, subgroup heterogeneity, and probable under-reporting of codeine use. Methodological constraints included low participant numbers, selection biases (admissions, help-seeking or co-medication sequelae as a proxy for neuroadaptation to codeine), and a lack of objective and standardised criteria for determining codeine dependence. Many studies employed internet-based recruitment or data collection, 33, 38 potentially limiting the generalisability of findings to users without regular internet access, but this might be offset by the ability to reach users who are otherwise difficult to reach. Some studies did not specify whether codeine was prescribed or obtained over the counter, but most reports were concerned with over-the-counter codeine. Many studies that included codeine-dependent people were excluded from our analysis because they did not separately describe codeine dependence; this particularly applied to studies of medication overuse headache. Nevertheless, our review is the most comprehensive synthesis of data on the phenomena of codeine dependence, and we have described a range of potential treatment responses, including medication-and non-medication-based treatments.
Conclusion
Codeine dependence can be identified by screening patients who present with acute complications associated with taking combination analgesics, and by routine questioning about over-thecounter medication use. Common treatment approaches include detoxification and opioid agonist treatment. Clinical leadership in providing guidance about how to identify and treat individuals with codeine dependence is required as a matter of public health.
